Lifestyle Drugs Market Growth Analysis and Forecast Report to 2021 February 2017

ReportsnReports . com adds new research report Global Lifestyle Drugs Market 2017-2021 . This report covers the present scenario and the growth prospects of the global lifestyle drugs market for 2017-2021 . To calculate the market size , the report considers sales of lifestyle drugs in the market .
Inquire for more information at http :// www . reportsnreports . com / contacts / inquirybeforebuy . aspx ? name = 917357
The following companies are the key players in the global lifestyle drugs market : Allergan , BMS , Eli Lilly , and Pfizer .
Other Prominent Vendors in the market are : Acerus Pharmaceuticals , Alkermes , Amorepacific , AndroScience , Anterios , AstraZeneca , Avanir Pharmaceuticals , Avolynt , Celtaxsys , Cerecor , Corcept Therapeutics , Cosmo Pharmaceuticals , CTC Bio , Dermira , Dong-A ST , Euthymics Bioscience , Foamix , Follicum , Forendo Pharma , Futura Medical Developments , Galderma , Hanmi Pharmaceutical , Incyte , Intrepid Therapeutics , Ion Channel Innovations , iX Biopharma , Johnson & Johnson , Legacy Healthcare , LEO Pharma , H . Lundbeck , Luye America Pharmaceuticals , Merck , Minerva Neurosciences , MSI Methylation Sciences , Neuralstem , Novan , Novartis , Novo-Nordisk , Palatin Technologies , Paratek Pharmaceuticals , Photocure , Revance Therapeutics , Rhythm Pharmaceuticals , S1 Biopharma , Sage Therapeutics , Samumed , Sanofi , Sigma-Tau Pharmaceuticals , Strategic Science & Technologies , Sumitomo Dainippon Pharma , Takeda , TetraLogic Pharmaceuticals , TherapeuticsMD , Valeant Pharmaceuticals , VistaGen Therapeutics , VIVUS , XBiotech , Yuhan , and Zafgen .
One trend in the market is the increase in M & A . The market has been witnessing an increase in M & A , which will lead to further consolidation . The vendors are pursuing inorganic growth strategies such as acquisitions and / or partnerships to expand their lifestyle drugs portfolio and to improve their presence in the market . For instance , in August 2015 , Allergan completed the acquisition of Naurex . The acquisition enhanced Allergan ' s portfolio of depression drugs with the addition of rapastinel , a Phase III-ready molecule that demonstrated rapid and sustained efficacy in multiple Phase II clinical studies in depression . With the patent expires in the market place , vendors are also looking to enhance their portfolio through acquisition of generics .
Purchase directly at http :// www . reportsnreports . com / purchase . aspx ? name = 917357
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry . The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors .
According to the report , one driver in the market is the lifestyle changes . Lifestyle changes such as physical inactivity , stress , consumption of fast foods , and limited intake of water can lead to the development of acne . Research studies report that people who are physically inactive are prone to develop insulin resistance compared with active individuals . Insulin resistance leads to the production of higher levels of sebum in the skin , resulting in acne development . Research studies also put forth that excess insulin can increase the levels of androgens in the body . High levels of androgens also lead to an increased production of sebum in the skin , resulting in acne development .